Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists

Author(s): Rawda Y. AlSheyyab*, Bashar M. Al-Taani, Rana M. Obeidat, Motasem M. Alsmadi, Rafeef K. Masaedeh, Raghda N. Sabat

Journal Name: Current Drug Delivery

Volume 15 , Issue 5 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.

Keywords: Cetrorelix, extrusion, GnHR antagonist, microparticles, peptide, subcutaneous, testesteron.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [602 - 609]
Pages: 8
DOI: 10.2174/1567201815666180214142300
Price: $65

Article Metrics

PDF: 41
PRC: 1